AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 291 min read$UTHR

ROTHBLATT MARTINE A sold $4.6M of UTHR (indirect holdings)

ROTHBLATT MARTINE A (Chairperson & CEO) sold 9,500 indirectly-held shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $480.85 ($472.43–$486.00, $4.57M total) across 14 trades on 2026-09-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · ROTHBLATT MARTINE A
Published Sep 29, 2026, 8:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 8:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short‑term positioning.

02

Market read

First‑time reporting of a $4.6M insider sale by the CEO, modest relevance for traders monitoring biotech stocks.

03

What to watch

Recent positive trial data or partnership announcements could offset the negative signal from the insider sale.

Relevance 5/10Novelty 6/10Timing: post‑market today

Background

Form 4 filing discloses insider transactions, a primary source for market participants.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

CEO/Chairperson Martine A. Rothblatt sold 9,500 shares for $4.6M via a 10b5‑1 plan, reducing her stake to 324,443 shares.

Expected impact

likely modest downside as market prices in the insider sale

Evidence & confidence

Sale size is moderate and pre‑arranged, so impact is limited but could prompt short‑term selling.

Market effects

Sector

Biotech/biopharma sector may see slight sell pressure from insider activity.

Regional

US equity markets, particularly small‑cap biotech segment.

Global

Limited to investors tracking United Therapeutics.

Counterpoint

What could challenge this read

The sale is pre‑arranged and may not reflect confidence; the stock could remain stable or rise on fundamentals.

Key entities

  • company
    United Therapeutics Corp

    US‑listed biotech firm (ticker UTHR).

  • person
    Martine A. Rothblatt

    Chairperson & CEO of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min